Safety, Tolerability, and Preliminary Efficacy of the Anti-Fibrotic Small Molecule PRI-724, a CBP/β-Catenin Inhibitor, in Patients with Hepatitis C Virus-related Cirrhosis: A Single-Center, Open-Label, Dose Escalation Phase 1 Trial

BACKGROUND: There is currently no anti-fibrotic drug therapy available to treat hepatitis C virus (HCV) cirrhosis. The aim of this study was to assess the safety, tolerability, and anti-fibrotic effect of PRI-724, a small-molecule modulator of Wnt signaling, in patients with HCV cirrhosis. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Kimura, Kiminori, Ikoma, Akemi, Shibakawa, Maki, Shimoda, Shinji, Harada, Kenichi, Saio, Masanao, Imamura, Jun, Osawa, Yosuke, Kimura, Masamichi, Nishikawa, Koji, Okusaka, Takuji, Morita, Satoshi, Inoue, Kazuaki, Kanto, Tatsuya, Todaka, Koji, Nakanishi, Yoichi, Kohara, Michinori, Mizokami, Masashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5605374/
https://www.ncbi.nlm.nih.gov/pubmed/28844410
http://dx.doi.org/10.1016/j.ebiom.2017.08.016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5605374/
https://www.ncbi.nlm.nih.gov/pubmed/28844410
http://dx.doi.org/10.1016/j.ebiom.2017.08.016

Ejemplares similares